Singular Genomics Announces Acquisition by Deerfield Management
Singular Genomics Systems, Inc. (Nasdaq: OMIC) has taken a significant step toward enhancing its operations by entering a definitive merger agreement to be acquired by Deerfield Management Company, L.P. This transaction, offering $20.00 per share, promises a remarkable 254% premium over the previous share price before the acquisition disclosure.
Strategic Merger Benefits for Singular Genomics
The Board of Directors at Singular Genomics established an independent Special Committee to explore strategic alternatives. This committee, composed of disinterested directors, played a crucial role in negotiating the terms of the merger with Deerfield. Following extensive consultations with independent financial and legal advisors, the Board unanimously approved the merger agreement.
Upon completion of this transaction, Singular Genomics will transition into a private entity. The Board believes that this change will provide the company with greater flexibility to pursue its mission of advancing scientific research and clinical applications.
Insights from Leadership
Andrew ElBardissi, M.D., Partner at Deerfield, expressed enthusiasm about the partnership, stating, “Singular Genomics has developed a state-of-the-art multi-omic spatial biology platform that empowers customers with innovative tools to unlock biological insights and drive breakthroughs in research and medicine.” This collaboration marks the beginning of an exciting new phase for Singular Genomics as it strives to innovate in scientific research.
Future Expectations and Closing Timeline
This acquisition is anticipated to finalize in the first half of 2025, contingent on the approval of Singular Genomics stockholders and the fulfillment of customary closing procedures. Notably, the deal does not hinge on financing conditions.
Strong Advisory Team in Place
Singular Genomics is supported by a robust advisory team throughout this process. TD Securities and Houlihan Lokey are acting as the financial advisors to the Board's Special Committee, while Gunderson Dettmer, LLP serves as the legal advisor for the company. Richards, Layton & Finger, P.A. is also offering counsel for the Special Committee, with Katten Muchin Rosenman LLP advising Deerfield.
About Singular Genomics
As a life sciences technology entity, Singular Genomics focuses on developing cutting-edge next-generation sequencing and multiomics technologies. One of its flagship products, the G4 Sequencing Platform, stands out as a versatile benchtop genomic sequencer, designed for efficiency and accuracy in genomic analysis. Furthermore, the company is in the process of developing the innovative G4X Spatial Sequencer, aimed at enhancing in situ readouts for various biological applications.
Overview of Deerfield Management
Deerfield Management is recognized for its extensive work in the healthcare investment sector, adopting a collaborative approach to drive progress in healthcare through investment, information, and philanthropy. Their mission involves connecting various elements of the healthcare ecosystem to foster innovation.
Contacts for Further Information
Investor Contact: Philip Trip Taylor, Gilmartin Group, ir@singulargenomics.com
Media Contact: Matt Browning, pr@singulargenomics.com
Frequently Asked Questions
What is the acquisition price per share for Singular Genomics?
The acquisition price is set at $20.00 per share, which reflects a substantial premium over recent closing values.
Who is acquiring Singular Genomics?
Singular Genomics is being acquired by an affiliate of Deerfield Management Company, L.P.
What benefits does Singular Genomics expect from going private?
Becoming a private company is expected to allow Singular Genomics greater operational flexibility to enhance its business strategy and innovation capabilities.
When is the expected date for the acquisition to close?
The acquisition is expected to close in the first half of 2025, pending stockholder approval and customary conditions.
What role did the Special Committee of the Board play in the acquisition?
The Special Committee, made up of independent directors, facilitated negotiations, evaluated strategic options, and recommended approval of the merger agreement to the Board.
